Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CRIS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.82% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.53M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 44107 | Beta 3.49 | 52 Weeks Range 1.40 - 17.49 | Updated Date 04/2/2025 |
52 Weeks Range 1.40 - 17.49 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -360.53% |
Management Effectiveness
Return on Assets (TTM) -45.06% | Return on Equity (TTM) -436.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5232243 | Price to Sales(TTM) 1.22 |
Enterprise Value -5232243 | Price to Sales(TTM) 1.22 | ||
Enterprise Value to Revenue 1.05 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 8466960 | Shares Floating 7070756 |
Shares Outstanding 8466960 | Shares Floating 7070756 | ||
Percent Insiders 7.83 | Percent Institutions 37.95 |
Analyst Ratings
Rating 4.33 | Target Price 21 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Founded in 2000, the company has historically focused on developing therapeutics based on pathways dysregulated in cancer, including Hedgehog and IRAK4.
Core Business Areas
- Drug Development: Curis focuses on the discovery, development, and commercialization of innovative drug candidates for cancer treatment. Their primary focus is on developing therapeutics targeting specific pathways in cancer cells.
- Partnerships and Licensing: Curis collaborates with other pharmaceutical and biotechnology companies to develop and commercialize its drug candidates through licensing agreements and partnerships.
Leadership and Structure
The leadership team includes the CEO, Chief Medical Officer, and other senior executives responsible for various aspects of the business. The organizational structure is typically functional, with departments for research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Emavusertib: Emavusertib is an investigational oral IRAK4 inhibitor. It is being developed for the treatment of hematologic malignancies. Currently in clinical trials. Competitors depend on the specific indication it is intended for once approved, and would include other targeted therapies and standard chemotherapy regimens.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and intense competition. Companies are constantly innovating and developing new treatments for diseases with unmet medical needs.
Positioning
Curis is a biotechnology company focused on targeted therapies for cancer. Its competitive advantages may include its specific technology platform and expertise in developing drugs targeting specific pathways in cancer cells.
Total Addressable Market (TAM)
The TAM for cancer therapies is substantial, reaching hundreds of billions of dollars globally. Curis is positioned to capture a portion of this market with its targeted therapies, but its success depends on the clinical efficacy and regulatory approval of its drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Partnerships with established pharmaceutical companies
- Targeted therapies addressing unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial results
- High risk of drug development failure
- Small market capitalization
Opportunities
- Positive clinical trial results
- Regulatory approval of drug candidates
- Expansion into new indications
- Acquisition by a larger pharmaceutical company
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory landscape
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- GILD
- BPMC
Competitive Landscape
Curis faces intense competition from larger, more established pharmaceutical companies. Its success depends on the unique efficacy profile of its drug candidates and its ability to secure partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial progress and partnership deals.
Future Projections: Future growth is highly dependent on the success of emavusertib clinical trials.
Recent Initiatives: Recent initiatives include advancing emavusertib through clinical trials and exploring potential partnerships.
Summary
Curis Inc. is a high-risk, high-reward biotechnology company focused on developing targeted cancer therapies. Its success hinges on the clinical trial results of emavusertib and its ability to secure funding and partnerships. The company faces intense competition and financial constraints but has the potential for significant growth if its drug candidates are successful. Curis needs to effectively manage its cash burn and navigate the complex regulatory landscape.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
BPMC
Blueprint Medicines Corp
BPMC
Blueprint Medicines Corp
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and investment decisions should be made based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://www.curis.com |
Full time employees 49 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.